Genzyme in the UK

Genzyme in the UK is dedicated to making a positive impact on the lives of people with serious diseases. Operating out of two locations we draw on the diverse talents of a 500-strong team. More>

Genzyme’s multiple sclerosis drug, Lemtrada®▼ (alemtuzumab) 12mg IV, highly commended at the 2014 UK Prix Galien

Genzyme, a Sanofi company, is delighted to announce that it has been highly commended at the 2014 UK Prix Galien Awards in the Innovative Product category for its multiple sclerosis therapy Lemtrada (alemtuzumab). Lemtrada, discovered at the University of Cambridge, further developed at both the Universities of Cambridge and Oxford, has been previously described by experts as a ground-breaking treatment for patients with relapsing-remitting multiple sclerosis (RRMS). More>

Aubagio® (teriflunomide), 14 mg tablet, a once-daily oral treatment for people with active relapsing-remitting multiple sclerosis is now available in the Republic of Ireland

Genzyme, a Sanofi Company, today welcomes the decision to make Aubagio available in the Republic of Ireland for the treatment of adults with active relapsing-remitting multiple sclerosis (RRMS). More>

Lemtrada®▼ (alemtuzumab) 12mg IV, a new treatment for adults with active relapsing remitting multiple sclerosis (RRMS), is recommended by NICE and now available in England

The National Institute for Health and Care Excellence (NICE), has announced today the final approval of Lemtrada as an option for treating adults with active RRMS, within its marketing authorisation. Patients with RRMS will now be able to access this new treatment on the NHS. More>

Search